A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs SEP 363856 (Primary) ; Amisulpride
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2016 Data from this trial will be presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), acording to a Sunovion Pharmaceuticals media release.
    • 23 Jul 2015 Status changed from recruiting to completed as per ClinicalTrial.gov record.
    • 29 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top